Capstone Therapeutics Corp (CAPS) financial statements (2020 and earlier)

Company profile

Business Address 1275 WEST WASHINGTON STREET
TEMPE, AZ 85281
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 11112
Cash and cash equivalents 11112
Other current assets 00001
Total current assets: 11113
Noncurrent Assets
Long-term investments and receivables     6
Long-term investments     6
Intangible assets, net (including goodwill) 00011
Intangible assets, net (excluding goodwill) 00011
Other undisclosed noncurrent assets     (6)
Total noncurrent assets: 00011
TOTAL ASSETS: 12123
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 00000
Accounts payable 00000
Accrued liabilities 00000
Total current liabilities: 00000
Noncurrent Liabilities
Long-term debt and lease obligation 2211 
Long-term debt, excluding current maturities 2211 
Total noncurrent liabilities: 2211 
Total liabilities: 32110
Stockholders' equity
Stockholders' equity attributable to parent (1)(1)(0)13
Common stock 00000
Additional paid in capital 190190189189189
Accumulated deficit (192)(191)(190)(189)(186)
Total stockholders' equity: (1)(1)(0)13
TOTAL LIABILITIES AND EQUITY: 12123

Income statement (P&L) ($ in millions)

6/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit: (2)    
Operating expenses (2)(2)(2)(3)(5)
Other undisclosed operating income 4    
Operating income (loss): 0(2)(2)(3)(5)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 0(0)(0)(0) 
Income (loss) from continuing operations before equity method investments, income taxes: 0(2)(2)(3)(5)
Other undisclosed loss from continuing operations before income taxes     (0)
Income (loss) from continuing operations before income taxes: 0(2)(2)(3)(5)
Income tax expense (benefit) (0)0000
Net income (loss): 0(2)(2)(3)(4)
Net income attributable to noncontrolling interest   1  
Net income (loss) available to common stockholders, diluted: 0(2)(1)(3)(4)

Comprehensive Income ($ in millions)

6/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss): 0(2)(2)(3)(4)
Comprehensive income (loss): 0(2)(2)(3)(4)
Comprehensive income, net of tax, attributable to noncontrolling interest   1  
Comprehensive income (loss), net of tax, attributable to parent: 0(2)(1)(3)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: